A cell-permeable peptidomimetic that prevents MLL1 (Mixed Lineage Leukemia 1) from complex assembling with WDR5 (Trp-Asp Repeat Domain 5), RbBP5 (Retinoblastoma Binding Protein 5), and ASH2L (Absent Small or Homeotic-2-Like) for enhanced H3K4 methyltransferase activity (IC50 = 0.4nM). Shown to reduce HoxA9 and Meis-1 mRNA expression in myeloblasts derived from MLL1-AF9-transduced murine bone marrow cells (50uM for 96 h) and preferentially inhibit the growth of MLL1-AF4-harboring MV4,11 and MLL1-ENL-harboring KOPN8 leukemia cultures (GI50 in 7 days = 25uM) via apoptosis induction, while exhibiting much reduced potency against BCR-ABL-dependent K562 cells (GI50 in 7 days = 84uM). Synonyms: (S)-N-(bis(4-Fluorophenyl)methyl)-1-(2-(2-ethyl-2-isobutyramidobutanamido)-5-guanidinopentanamido)cyclopentanecarboxamide, TFA, Histone Methyltransferase Inhibitor IX, MM102 Molecular Formula: C35H49F2N7O4 CF3CO2H Solubility: DMSO Primary Target: WDR5 Primary Target Ki: 1nM Storage and Stability: Store at -20C under inert atmosphere. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Purity:
95% (HPLC)
Form:
Supplied as a light beige powder.
* VAT and and shipping costs not included. Errors and price changes excepted